FODMAPs: Emerging Science and Implications for Practice

Similar documents
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.

Gut microbiota in IBS and its modification by diet: probiotics, prebiotics and low FODMAP diet

Dietary fibre: an old concept in new light

Latest research on fibre and gut health

FODMAPs: Major role in food sensitivities

NW SMS icons. MFLN Intro

Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity

Low FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015

William D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology

A gut health approach to metabolic health.

The relationship between FODMAP intake and acute gastrointestinal symptoms in adults with IBS A novel analysis using the FAST Diary

Amy Bernhard, MS, ACSM-CES Dietetic Intern Morrison Chartwell s Dietetic Internship

Title: Low FODMAP in 2017: Lessons learned from clinical trials and mechanistic studies.

Re-challenging FODMAPs: the low FODMAP diet phase two

The role of FODMAPs in irritable bowel syndrome

Irritable Bowel Syndrome

An Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome

What to expect? What IBS is and how this manifests as functional symptoms. How IBD creates functional symptoms for individuals in remission

The Roadmap to FODMAP

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

Coeliac disease (CD) and other dietary restrictions- which nutrients are at risk?

Restriction of Dietary Short Chain Carbohydrates may Attenuate Symptoms of Irritable Bowel Syndrome in Athletes Short Review

William D. Chey, MD Professor of Medicine University of Michigan

King s Research Portal

Irritable Bowel Syndrome

Bringing the Low FODMAP Diet into your Nutrition Practice

Treatment of IBS - Diet or Drugs?

4/14/2018 LEARNING OBJECTIVES

Gluten Free Alphabet Soup!

Dietitian Connection Webinar: Dietary management of IBS the low FODMAP diet & other adjunct therapies. Presented by Shirley Webber and Dr Jane Varney

Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence

Slide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update

New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome

9/12/2017. Introduction. NHMRC Recommendations. Food Standards Australia New Zealand (FSANZ) defines Dietary Fibre as follows:

FODMAPs. Presented by: Joanna Baker Date: 18 th May 2018

The Role of Food in the Functional Gastrointestinal Disorders

Irritable Bowel Syndrome

Rome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC

with DIARRHEA (IBS-D)

State of the Art: Management of Irritable Bowel Syndrome

What I will cover today

Inflammatory bowel disease (IBD) is characterized by inflammation

Management and Lifestyle Advice for Adults with Irritable Bowel Syndrome Information for Patients

Restriction of FODMAP in the management of bloating in irritable bowel syndrome

What is Irritable Bowel Syndrome (IBS)?

I. Identification Presenters: Date: Name of Organization: Goal Statement: Title of Presentation: Audience Description: Physical Set-up: -

Irritable Bowel Syndrome (IBS) and other Functional Bowel Disorders

A FODMAP Diet Update: Craze or Credible?

70% Did you know % of the UK population suffer from IBS. are women. Adding up to 13 million individuals having stomach problems

The Beginner s Guide To A D.I.Y Low FODMAP Diet

Your 'gluten sensitivity' might not have anything to do with gluten

What s the Latest? Rome III Criteria for IBS

Use of Low FODMAP diet in Scotland. Presented by Mairéad Keegan Dietetic Team Lead, Hairmyres Hospital, NHS Lanarkshire

Dietary Interventions for IBS, IBD & Coeliac Disease. Debbie Blissitt Registered Dietitian

Hompes Method. Practitioner Training Level II. Lesson Eight Part 1C SIBO Protocols

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

Inflammatory or Irritable? (the bowel, not the speaker)

30/07/2018. Defining Fibre - Challenges & Controversies. Fibre Definitions

Spectrum of Gluten and Wheat Related Disorders

New Insights into Functional Bowel Disorders. Diagnostic and Non medical Treatment Challenges in IBS

King s Research Portal

WHOLE HEALTH: INFORMATION FOR VETERANS. Eating to Reduce Irritable Bowel Symptoms: The FODMaP Diet

GI Complications in heds and HSD

Refractory IBS-D: An Evidence-Based Approach to Therapy

Irritable Bowel Syndrome (IBS)

GETTING REAL WITH GUT HEALTH

IBS The Physiologist s Perspective

Irritable bowel syndrome in adults

Accepted Manuscript. Prebiotics Versus Low Fodmap Diet: An Interpretative Nightmare. Jane Varney, Jane G. Muir, Peter R. Gibson

5 Things to Know About Irritable Bowel Syndrome

Unlocking the mysteries of gut comfort

Geographical and Cultural Food-related Symptoms, Food Avoidance and Elimination

Helpful Resources and Links and. Research Papers, Studies and Donations

Nutrition and IBD. IBD Talk. Presented by. Hannah Price, paediatric dietitian at RHH. Lauren Farquhar, adult dietitian at RHH

The role of gut microbiome in IBS

Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61

Irritable Bowel. Syndrome. Health Promotion Service

6/27/2018. Disclosures OBJECTIVES. William Chey, MD: Consultant: Nestle, Campbells; Grants and Research Support: Fody Foods, Nestle, Zespri

Non coeliac gluten sensitivity: Clinical relevance and recommendations for future research

Unlocking the mysteries of gut comfort

Managing dietary problems in pancreatic cancer Contents

Irritable bowel syndrome: the latest thinking

Clinical problems related to GI involvement in SSc

Physiology of the gut and mechanisms of prebiotic effect. Joanne Slavin, Ph.D, R.D. Department of Food Science and Nutrition University of Minnesota

Gut microbiota: importance

Poor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders

What Is the Low-FODMAP Diet?

Heidi M. Staudacher, Peter M. Irving, Miranda C. E. Lomer and Kevin Whelan

IBS Practical Advice for Patients

Diet, Nutrition and Inflammatory

Managing irritable bowel syndrome: The low-fodmap diet

The Secrets of your Irritable Bowel Syndrome (IBS)

Modulation of gut microbiota for

FODMAPS: Presenta(on Overview

Irritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM

DIETARY ADVICE FOR CONSTIPATION

Examining the effects of pre and probiotics on gut microbiota during the ageing process

From Food Map to FODMAP in Irritable Bowel Syndrome

Transcription:

FODMAPs: Emerging Science and Implications for Practice Megan Rossi, PhD RD @DrMegan_RD @Dr_Megan www.drmeganrossi.com

BDA guidelines for dietary management of IBS 1) Healthy eating and lifestyle Alcohol Caffeine Spicy food Fatty food Fluid intake Eating habits 2) Milk and dairy restriction 3) Dietary fibre Adapted from McKenzie. J Hum Nutr Diet. 2016; 29: 576-59 2

What is the low FODMAP diet? F ermentable Short chain CHO O ligo-saccharides many sugar units Fructans, Galactooligosaccharides D M i-saccharides two sugar units ono-saccharides one sugar unit Lactose Fructose MECHANISMS OF ACTION SUMMARY OF LITERATURE CONSIDERATIONS FOR PRACTICE A nd P olyols Sugar alcohols e.g sorbitol, mannitol 3

How FODMAPs induce symptoms: key components Osmotic load Bacterial fermentation Colonic hypersensitivity Symptom induction 4

1. Osmotic load n=16 healthy people Fructose (40g) Fructans (40g) Fructose + glucose (40g each) Glucose (placebo, 40g) MRI repeated hourly- 5 hrs Small bowel water content Murray et al, Am J Gastro. 2014; 109: 110-119 5

2. Bacterial fermentation n=16 healthy people Fructose (40g) Fructans (40g) Fructose + glucose (40g each) Glucose (placebo, 40g) MRI repeated hourly- 5 hrs Colonic gas volume Murray et al, Am J Gastro. 2014; 109: 110-119 6

1. Osmosis + 2. fermentation Staudacher, Nature Gastro 2014; 11: 256 OSMOTIC LOAD FERMENTATION Adapted from Prof Whelan

3. Colonic hypersensitivity n=29 healthy n=29 IBS >1 week washout Fructose (40g) Fructans (40g) Glucose (placebo, 40g) >1 week washout Fructose (40g) Fructans (40g) Glucose (placebo, 40g) Fructose (40g) Fructans (40g) Glucose (placebo, 40g) MRI repeated hourly- 5 hrs Small Colonic Symptom bowel gas water volume Intensity content 8 Major et al, Gut. 2014; In Press

How FODMAPs induce symptoms: key components Osmotic load Bacterial fermentation Colonic hypersensitivity Symptom induction 9

Dose-response relationship n=25 IBS Shepherd et al, ClinGastro Hep 2008; 6: 765 771 2 weeks >10 day washout 2 weeks Fructose (low, med, high) Fructans (low, med, high ) Fructose+Fructans (low, med, high ) Glucose (low, med, high) Fructose Fructans Fructose + fructans Glucose (low, med, high) (low, med, high ) (low, med, high ) (low, med, high) Symptom severity *Dose dependent difference p<0.002 for all groups (except glucose) 10

Body of evidence for the low FODMAP diet 10 studies RCT Sham diet Other best practice advice > 30 studies Increased quality of clinical ev vidence Cohort studies Case Control studies Case series, case reports Standardised diet Usual diet Types of controls (comparators) Hierarchy of study design 11

10 Randomised comparative trials References Responders Comparators Comparator FODMAP Eur J Nutrition, 2016 Staudacher 2012, J Nutr 23% 68% Abdominal pain Usual diet OR 1.81 Pedersen 2014, World J Gastro (-34/500) (-133/500) Population excl. IBS-C, n=41 All,n=82 Typical diet Halmos 2014, Gastro - (44.9/100) 70% (22.8/100) All, n=30 High FODMAP McIntosh 2016, Gut Ong 2010, J Gastro Hepatol GI symptoms 21% OR 1.81 (6/9) 72% (2/9) All (2 IBS-C), n=40 All, n=15 Hustoft 2016, Neurogastro Motil 30% 80% IBS- D&M, n=20 Placebo diet Staudacher 2016, DDW 42% 73% excl. IBS-C, n=104 IBS-SSS score Bohn 2015, Gastro OR 0.44 46% 50% All, n=75 Active intervention Peters 2016, Alim Pharm Ther Eswaran 2016, Am J Gastroentrol 72% 41% 71% 52% All, n=74 IBS-D, n=92

First RCT-Usual vs. Low FODMAP diet IBS (excl IBS-C) n=41 Control n=22 (Usual diet) Intervention n=19 (Low FODMAP) 4 weeks Gastrointestinal Symptom Rating Scale Global symptom question Do you have adequate relief of your IBS symptoms? Controls 23% FODMAP 68% P = 0.003 Staudacher et al, J Nutrition 2012; 142: 1510-19 Placebo effect? 13

Randomised comparative trials References Responders Comparators Comparator FODMAP Population Usual diet Staudacher 2012, J Nutr Pedersen 2014, World J Gastro 23% (-34/500) 68% (-133/500) excl. IBS-C, n=41 All,n=82 Typical diet Halmos 2014, Gastro - (44.9/100) 70% (22.8/100) All, n=30 McIntosh 2016, Gut 21% 72% All (2 IBS-C), n=40 High FODMAP Ong 2010, J Gastro Hepatol (6/9) (2/9) All, n=15 Hustoft 2016, Neurogastro Motil 30% 80% IBS- D&M, n=20 Placebo diet Staudacher 2016, DDW 42% 73% excl. IBS-C, n=104 Bohn 2015, Gastro 46% 50% All, n=75 Active intervention Peters 2016, Alim Pharm Ther 72% 71% All, n=74 Eswaran 2016, Am J Gastroentrol 41% (23%) 52% (51%*) IBS-D, n=92

Typical vs. Low FODMAP diet IBS n=30 3 week 3 week washout 3 week Typical Aus Diet Typical Aus Diet Low FODMAP Low FODMAP Composite GI symptom score Dissatisfaction with stool consistency Pain, bloating, wind, stool consistency Does it work in the real world? Objective stool measures Halmos et al, Gastroenterology 2014; 146: 67 75

Randomised comparative trials References Responders Comparators Comparator FODMAP Population Usual diet Staudacher 2012, J Nutr Pedersen 2014, World J Gastro 23% (-34/500) 68% (-133/500) excl. IBS-C, n=41 All,n=82 Typical diet Halmos 2014, Gastro - (44.9/100) 70% (22.8/100) All, n=30 McIntosh 2016, Gut 21% 72% All (2 IBS-C), n=40 High FODMAP Ong 2010, J Gastro Hepatol (6/9) (2/9) All, n=15 Hustoft 2016, Neurogastro Motil 30% 80% IBS- D&M, n=20 Placebo diet Staudacher 2016, DDW 42% 73% excl. IBS-C, n=104 Bohn 2015, Gastro 46% 50% All, n=75 Active intervention Peters 2016, Alim Pharm Ther 72% 71% All, n=74 Eswaran 2016, Am J Gastroentrol 41% (23%) 52% (51%*) IBS-D, n=92

Sham vs. Low FODMAP diet IBS (excl. IBS-C) n=104 Sham diet n=53 Low FODMAP n=51 4 weeks Gastrointestinal Symptom Rating Scale IBS symptom severity scoring Sham Low FODMAP Placebo Real world How does it compare to other therapies? 17

Randomised comparative trials References Responders Comparators Comparator FODMAP Population Usual diet Staudacher 2012, J Nutr Pedersen 2014, World J Gastro 23% (-34/500) 68% (-133/500) excl. IBS-C, n=41 All,n=82 Typical diet Halmos 2014, Gastro - (44.9/100) 70% (22.8/100) All, n=30 McIntosh 2016, Gut 21% 72% All (2 IBS-C), n=40 High FODMAP Ong 2010, J Gastro Hepatol (6/9) (2/9) All, n=15 Hustoft 2016, Neurogastro Motil 30% 80% IBS- D&M, n=20 Placebo diet Staudacher 2016, DDW 42% 73% excl. IBS-C, n=104 Bohn 2015, Gastro 46% 50% All, n=75 Active intervention Peters 2016, Alim Pharm Ther 72% 71% All, n=74 Eswaran 2016, Am J Gastroentrol 41% (23%) 52% (51%*) IBS-D, n=92

First-line vs. Second-line dietary management IBS n=75 1 st line n=37 Low FODMAP n=38 4 weeks IBS-SSS Lower response to LFD: 68-80% Suboptimal? 1 Low FODMAP dietary advice eg. consumption of spelt bread Dietary data Significant reduction in fat 50% 46% 1. Gibson. J Gastroenterology, 150: 1046-7, 2016. 19

Randomised comparative trials References Responders Comparators Comparator FODMAP Population Usual diet Staudacher 2012, J Nutr Pedersen 2014, World J Gastro 23% (-34/500) 68% (-133/500) excl. IBS-C, n=41 All,n=82 Typical diet Halmos 2014, Gastro - (44.9/100) 70% (22.8/100) All, n=30 McIntosh 2016, Gut 21% 72% All (2 IBS-C), n=40 High FODMAP Ong 2010, J Gastro Hepatol (6/9) (2/9) All, n=15 Hustoft 2016, Neurogastro Motil 30% 80% IBS- D&M, n=20 Placebo diet Staudacher 2016, DDW 42% 73% excl. IBS-C, n=104 Bohn 2015, Gastro 46% 50% All, n=75 Active intervention Peters 2016, Alim Pharm Ther 72% 71% All, n=74 Eswaran 2016, Am J Gastroentrol 41% (23%) 52% (51%*) IBS-D, n=92

Emerging science: evidence beyond symptom response References Responders Comparators Comparator FODMAP Population Usual diet Staudacher 2012, J Nutr Pedersen 2014, World J Gastro 23% (-34/500) 68% (-133/500) excl. IBS-C, n=41 All,n=82 Typical diet Halmos 2014, Gastro - (44.9/100) 70% (22.8/100) All, n=30 McIntosh 2016, Gut 21% 72% All (2 IBS-C), n=40 High FODMAP Ong 2010, J Gastro Hepatol (6/9) (2/9) All, n=15 Hustoft 2016, Neurogastro Motil 30% 80% IBS- D&M, n=20 Placebo diet Staudacher 2016, DDW 42% 73% excl. IBS-C, n=104 Bohn 2015, Gastro 46% 50% All, n=75 Active intervention Peters 2016, Alim Pharm Ther 72% 71% All, n=74 Eswaran 2016, Am J Gastroentrol 41% 52% IBS-D, n=92 21

Emerging science: evidence beyond symptom response IBS n=40 High FODMAP n=20 Low FODMAP n=20 3 weeks IBS Severity Scoring System 21% vs. 72% (p<0.009) IBS-D & M n=20 Low FODMAP 3 weeks IBS Severity Scoring System 100% 8 fold (p<0.05) 22

MECHANISMS OF ACTION SUMMARY OF THE LITERATURE CONSIDERATIONS FOR PRACTICE Clinical Guidelines Level D evidence is limited

MECHANISMS OF ACTION SUMMARY OF LITERATURE CONSIDERATIONS FOR PRACTICE What happens in practice? 3- step process Restriction (3-6 weeks) Re-introduction challenge (3 day/ challenges) Personalisation (long term) KEY: total FODMAP load at one meal and per day Copyright King s College London

MECHANISMS OF ACTION SUMMARY OF EVIDENCE CONSIDERATIONS FOR PRACTICE Resources: Getting App y Restriction (3-6 weeks) Re-introduction challenge (3 day/ challenges) Personalisation (long term)

MECHANISMS OF ACTION SUMMARY OF THE LITERATURE CONSIDERATIONS FOR PRACTICE Cautions and limitations Nutrition adequacy Gut microbiota Staudacher et al 2012 J Nutr 142:1510-1518 Staudacher et al 2012 J Nutr 142:1510-1518 Delivery cost Halmos et al 2014 Gastro 146:67-75 139.20 per patient vs. 67.19 per patient Hustoftet al 2016 Bohn et al 2016 (UEG)

Summary Mechanisms underpinning the diet Osmotic load + fermentation + colonic hypersensitivity Whom can we help the most Those with pain, bloating&/or diarrhoea Emerging science: Evidence beyond symptom control Immune regulation Implications for practice 3 step process, dietitian-led Caution nutrition deficiencies 27

@ _ @ _ @ Prof Kevin Whelan Dr Miranda Lomer Dr Peter Irving Heidi Staudacher Dr Jane Muir Prof Peter Gibson Prof Robin Spiller Dr Luca Dr Giles Major

MECHANISMS OF ACTION SUMMARY OF EVIDENCE CONSIDERATIONS FOR PRACTICE What happens in practice? 3- step process Restriction (3-6 weeks) Re-introduction challenge (3 day/ challenges) Personalisation (long term) KEY: total FODMAP load at one meal and per day Copyright King s College London

MECHANISMS OF ACTION SUMMARY OF EVIDENCE CONSIDERATIONS FOR PRACTICE Credibility of resources > 2.3 million results (24/10/16) Accuracy of data? Not comprehensive too restrictive Conflicting

MECHANISMS OF ACTION SUMMARY OF EVIDENCE CONSIDERATIONS FOR PRACTICE Resources: Getting App y Restriction (3-6 weeks) Re-introduction challenge (3 day/ challenges) Personalisation (long term)

Who is the diet for? Rome IV http://www.balancedgrub.com

Emerging science: evidence beyond symptom response? IBS n=40 High FODMAP n=20 Low FODMAP n=20 IBS-D & M n=20 Low FODMAP (LFD) 3 wks 3 weeks LFD + FOS LFD + placebo IBS Severity Scoring System 21% vs. 72% (p<0.009)***mechanisms OF ACTION LFD + *** FOS Dysfunctional signalling between SCFA & mast cells 8 fold (p<0.05) 3 wks LFD + placebo IBS Severity Scoring System 30% vs. 80% (p=0.013) Mechanically induced mast cell degranulation Dietary artefact/ confounders? 10 days 10 days 33

Predicting response 34

Randomised comparative trials Responders References Comparators Comparator FODMAP Usual diet Typical diet Staudacher, 2012 Pedersen, 2014 Halmos, 2014 23% (-34/500) - (22.8/100) 68% Specific symptoms Stool frequency & consistency, bloating, pain, flatulence Pain,distension, satisfaction with (-133/500) IBS, n=82 bowels Both IBS-D &C, BUT stool 70% (44.9/100) Bloating, pain, wind frequency + IBS, n=30 form only IBS-D Population IBS-C (12%), NS IBS-D&M, n=41 High FODMAP McIntosh, 2016 Ong, 2010 21% (6/9) 72% (2/9) Pain intensity, satisfaction with IBS, n=40 bowels, distension NS Only 5% IBS-C Pain, bloating, flatus, nausea, heartburn, lethargy IBS, n=15 Placebo diet Hustoft, 2016 30% 80% Pain, distention, bowel habit* IBS- D&M, n=20 Staudacher, 2016 42% 73% Pain, bloating, flatulence, urgency IBS(excl-C), n=104 Active intervention Bohn, 2015 Peters, 2016 Eswaran, 2016 46% 72% 41% 50% 71% 52% Stool frequency (within grp) No difference Pain (51% vs 23%*) IBS, n=75 IBS, n=74 IBS-D, n=92 35

36

Comparing total FODMAP intakes What quantity of FODMAPs (g) defines a low FODMAP diet? What is the threshold of FODMAPs (g) needed to see a reduction in symptoms? Total FODMAP intake (g) Study Control diet Low FODMAP diet Halmos et al, 2014 23.7 (typical Australian diet) Staudacheret al, 2012 29.6 (typical UK diet) Long Term Study, 2015 29.4 (normal diet) 3.05 17.7 20.9

38